利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.054 秒)

    Method for producing modified glycoproteins
    22.
    发明申请
    Method for producing modified glycoproteins 审中-公开
    生产改性糖蛋白的方法

    公开(公告)号：US20070105127A1

    公开(公告)日：2007-05-10

    申请号：US11271217

    申请日：2005-11-10

    申请人： Tillman Gerngross

    发明人： Tillman Gerngross

    IPC分类号： C40B30/06 ,  C40B40/08

    CPC分类号： C12P21/005 ,  C07K2319/04 ,  C07K2319/05 ,  C12N1/14 ,  C12N9/1048 ,  C12N9/2488 ,  C12N15/79 ,  C12N15/80 ,  C12N15/81 ,  C12Y302/01 ,  C12Y302/01113

    摘要： Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways. This is achieved using a combination of engineering and/or selection of strains which: do not express certain enzymes which create the undesirable complex structures characteristic of the fungal glycoproteins, which express exogenous enzymes selected either to have optimal activity under the conditions present in the fungi where activity is desired, or which are targeted to an organelle where optimal activity is achieved, and combinations thereof wherein the genetically engineered eukaryote expresses multiple exogenous enzymes required to produce “human-like” glycoproteins.

    摘要翻译： 已经开发了具有遗传修饰的糖基化途径的细胞系，其允许它们进行模拟人类中糖蛋白的加工的酶反应序列。 在这些工程化宿主中表达的重组蛋白可以产生与其对应物更相似的糖蛋白（如果基本上不相同）。 通常产生含有高甘露糖的N-聚糖（包括单细胞和多细胞真菌）的低等真核生物被修饰以产生N-聚糖，例如Man 3或GlcNAc 2 N或其它结构 沿着人类糖基化途径。 这是使用以下工程和/或选择的组合实现的：不表达产生真菌糖蛋白特征的不合需要的复合结构的某些酶，其表达选择在真菌中存在的条件下具有最佳活性的外源酶 其中需要活性或靶向实现最佳活性的细胞器，以及其组合，其中遗传工程真核生物表达产生“人样”糖蛋白所需的多种外源酶。

    Production of modified glycoproteins having multiple antennary structures
    23.
    发明申请
    Production of modified glycoproteins having multiple antennary structures 失效
    具有多个触角结构的修饰的糖蛋白的生产

    公开(公告)号：US20070037248A1

    公开(公告)日：2007-02-15

    申请号：US10546101

    申请日：2004-02-20

    申请人： Piotr Bobrowicz ,  Stephen Hamilton ,  Tillman Gerngross ,  Stefan Wildt ,  Byung-Kwon Choi ,  Juergen Nett ,  Robert Davidson

    发明人： Piotr Bobrowicz ,  Stephen Hamilton ,  Tillman Gerngross ,  Stefan Wildt ,  Byung-Kwon Choi ,  Juergen Nett ,  Robert Davidson

    IPC分类号： C07K14/47 ,  C07H21/04 ,  C12P21/06 ,  C12N1/18 ,  C12N15/74

    CPC分类号： C12P21/005 ,  C12N9/1051

    摘要： The present invention relates to eukaryotic host cells, especially lower eukaryotic host cells, having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar and sugar nucleotide transporters to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells exhibit GnTIII, GnTIV, GnTV, GnT VI or GnTIX activity, which produce bisected and/or multiantennary N-glycan structures and may be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar, sugar nucleotide transporters, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.

    摘要翻译： 本发明涉及具有修饰的寡糖的真核宿主细胞，特别是较低的真核宿主细胞，其可以通过异源表达一组糖基转移酶，糖和糖核苷酸转运蛋白进一步修饰，以成为用于产生哺乳动物的宿主菌株， 人类治疗糖蛋白。 该方法提供了可用于表达和靶向参与糖基化的任何所需基因的工程化宿主细胞。 制备或选择具有修饰的脂质连接寡糖的宿主细胞。 在工程化宿主细胞中制备的N-聚糖表现出GnTIII，GnTIV，GnTV，GnT VI或GnTIX活性，其产生二等分和/或多元N-聚糖结构，并且可以通过异源表达一种或多种酶，例如糖基转移酶 ，糖，糖核苷酸转运蛋白，以产生人样糖蛋白。 为了生产治疗性蛋白质，该方法可适用于工程化可能获得任何所需糖基化结构的细胞系。

    Methods for producing modified glycoproteins
    25.
    发明申请
    Methods for producing modified glycoproteins 有权

    公开(公告)号：US20060177898A1

    公开(公告)日：2006-08-10

    申请号：US11249061

    申请日：2005-10-11

    申请人： Tillman Gerngross

    发明人： Tillman Gerngross

    IPC分类号： C12P21/06 ,  C12N1/18 ,  C12N1/16 ,  C12N15/74 ,  C12N9/24 ,  C12N9/10

    CPC分类号： C12P21/005 ,  C07K2319/04 ,  C07K2319/05 ,  C12N1/14 ,  C12N9/1048 ,  C12N9/2488 ,  C12N15/79 ,  C12N15/80 ,  C12N15/81 ,  C12Y302/01 ,  C12Y302/01113

    摘要： Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways. This is achieved using a combination of engineering and/or selection of strains which: do not express certain enzymes which create the undesirable complex structures characteristic of the fungal glycoproteins, which express exogenous enzymes selected either to have optimal activity under the conditions present in the fungi where activity is desired, or which are targeted to an organelle where optimal activity is achieved, and combinations thereof wherein the genetically engineered eukaryote expresses multiple exogenous enzymes required to produce “human-like” glycoproteins.

    Methods for producing modified glycoproteins
    26.
    发明申请
    Methods for producing modified glycoproteins 有权

    公开(公告)号：US20060078963A1

    公开(公告)日：2006-04-13

    申请号：US11240432

    申请日：2005-09-30

    申请人： Tillman Gerngross

    发明人： Tillman Gerngross

    IPC分类号： C12P21/06 ,  C12N9/10 ,  C07K14/47

    CPC分类号： C12P21/005 ,  C07K2319/04 ,  C07K2319/05 ,  C12N1/14 ,  C12N9/1048 ,  C12N9/2488 ,  C12N15/79 ,  C12N15/80 ,  C12N15/81 ,  C12Y302/01 ,  C12Y302/01113

    摘要： Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways. This is achieved using a combination of engineering and/or selection of strains which: do not express certain enzymes which create the undesirable complex structures characteristic of the fungal glycoproteins, which express exogenous enzymes selected either to have optimal activity under the conditions present in the fungi where activity is desired, or which are targeted to an organelle where optimal activity is achieved, and combinations thereof wherein the genetically engineered eukaryote expresses multiple exogenous enzymes required to produce “human-like” glycoproteins.

    Removing endotoxin with an oxdizing agent from polyhydroxyalkanoates produced by fermentation
    30.
    发明授权
    Removing endotoxin with an oxdizing agent from polyhydroxyalkanoates produced by fermentation 失效
    用氧化剂从发酵产生的聚羟基链烷酸酯中去除内毒素

    公开(公告)号：US06245537B1

    公开(公告)日：2001-06-12

    申请号：US09076198

    申请日：1998-05-12

    申请人： Simon F. Williams ,  David P. Martin ,  Tillman Gerngross ,  Daniel M. Horowitz

    发明人： Simon F. Williams ,  David P. Martin ,  Tillman Gerngross ,  Daniel M. Horowitz

    IPC分类号： C12P762

    CPC分类号： C12P7/625 ,  A61B17/06166 ,  A61B42/00 ,  A61K47/593 ,  A61K47/6957 ,  A61L15/26 ,  A61L17/10 ,  A61L27/18 ,  A61L27/34 ,  A61L29/06 ,  A61L31/06 ,  C08G63/06 ,  C08G63/6852 ,  C08G63/6882 ,  C08G63/912 ,  C12N5/0068 ,  C12N2533/30 ,  Y10S977/775 ,  Y10T428/139 ,  C08L67/04

    摘要： Polyhydroxyalkanoate (PHA) that contains a pyrogen such as endotoxin due to a process of producing the PHA is treated to remove the pyrogen by a process that does not affect the inherent chemical and physical properties of the PHA to obtain a biocompatible PHA. PHA produced by fermentation with a Gram negative bacteria can be treated with an oxidizing agent such as hydrogen peroxide or benzoyl peroxide to reduce the endotoxin content to less than 20 endotoxin units/gram of PHA to produce PHA that does not elicit an acute inflammatory response when implanted in an animal. The PHA may have a melting point or glass transition temperature less than 136° C., and can be chemically modified or derivatized such as by covalently coupling an attachment or targeting molecule. The PHA may be used to form various medical devices, and can be used for in vivo applications including tissue coatings, stents, sutures, tubing, bone and other prostheses, bone and tissue cements, tissue regenerating devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses.

    摘要翻译： 处理由于产生PHA的过程而含有热原如内毒素的聚羟基链烷酸酯（PHA），以通过不影响PHA固有的化学和物理性能以获得生物相容性PHA的方法除去热原。 通过用革兰氏阴性细菌发酵产生的PHA可以用氧化剂如过氧化氢或过氧化苯甲酰处理以将内毒素含量降低到小于20个内毒素单位/克的PHA，以产生不引起急性炎症反应的PHA 植入动物。 PHA可以具有低于136℃的熔点或玻璃化转变温度，并且可以通过共价偶联附着物或靶向分子进行化学修饰或衍生化。 PHA可以用于形成各种医疗装置，并且可以用于体内应用，包括组织涂层，支架，缝线，管，骨和其他假体，骨和组织水泥，组织再生装置，伤口敷料，药物递送和 用于诊断和预防用途。